| abstract |
This invention relates to benzodiazepine derivatives, compositions comprising ntherapeutically effective amounts of those benzodiazepine derivatives and methods of nusing those derivatives or compositions in treating cognitive impairment associated with ncentral nervous system (CNS) disorders. In particular, it relates to the use of a a5ncontaining GABAA receptor agonist (e.g., a 5-containing GABAA receptor positive nallosteric modulator) as described herein in treating cognitive impairment associated with ncentral nervous system (CNS) disorders in a subject in need or at risk thereof, including, nwithout limitation, subjects having or at risk for age-related cognitive impairment, Mild nCognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory nImpairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's nDisease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, nbipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive nimpairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, nfragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. |